NASAL SPRAY INDICATED FOR SINUSITIS SYMPTOMS
Nasodren® has shown efficacy for most common sinusitis symptoms such as:
- NASAL CONGESTION
- NASAL DISCHARGE (anterior/posterior nasal drip)
- HEADACHE
- LOSS OF SMELL
Watch Nasodren® Spot
What is Nasodren®?
-
-
100% NATURAL - PRESERVATIVE FREE
Nasodren® is a 100% natural product, based on Cyclamen europaeum extract.
Nasodren® is manufactured using the most innovative pharmaceutical technologies, in accordance with the Good Manufacturing Practices (GMP) quality system.
What makes Nasodren® different?
-
ONLY ONCE A DAY
Nasodren® only needs to be sprayed once a day, providing 24h of relief.
-
UNIQUE MODE OF ACTION
Nasodren® clears and drains both the nose and sinuses, making the product unique in the treatment of sinusitis symptoms.
-
HIGH SAFETY PROFILE
Nasodren® does not produce a rebound effect, dependence or tolerance.
-
MORE THAN 18 YEARS OF SUCCESS
Produced by Hartington Pharma Ltd. - World leader in modern approaches to sinusitis treatment.
Learn about Nasodren® Mode of Action
Clinically proven efficacy
- FDA
EFFICACY SHOWN IN U.S. MULTICENTRE CLINICAL TRIAL
Conducted in 25 sites in USA (2007), 'Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis' is the only study for sinusitis that has ever used the most objective possible methods available -Computed Tomography- to select patients and assess outcomes. Nasodren® showed high efficacy and safety in sinusitis treatment.
The study result 'An exploratory trial of Cyclamen europaeum extract for acute rhinosinusitis' is published in The Laryngoscope (Official Journal of The American Laryngological, Rhinological and Otological Society).
-
INCLUDED IN THE EPOS2012 GUIDELINES
Nasodren® is included in the newest edition of European Guidelines for Sinusitis treatment (EPOS2012) with the highest strength of recommendation and evidence.
-
PUBLISHED CLINICAL TRIALS
Efficacy and safety of Nasodren® have been shown in many different Clinical Trials conducted worldwide, involving more than 2.000 participants. The results of these Clinical Trials are published in the most relevant ENT professional journals. The latest studies to be published are:
- Mullol J, Crespo C, Carré C, Brosa M. Pharmacoeconomics of Cyclamen europaeum in the Management of Acute Rhinosinusitis. The Laryngoscope (Official Journal of The American Laryngological, Rhinological and Otological Society) 123: 2620-2625, 2013. PMID: 23670920.
- Pfaar O, Mullol J, Anders C, Hormann K, Klimek L. Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo-controlled trial. Rhinology (Official Organ of the International and European Rhinologic Societies). Mar;50(1):37-44, 2012. PMID: 22469604.
- Ponikau J, Hamilos D, Barreto A, Cecil J, Jones S, Manthei S. An exploratory trial of Cyclamen europaeum extract for acute rhinosinusitis. The Laryngoscope (Official Journal of The American Laryngological, Rhinological and Otological Society). Sep; 122(9): 1887-91, 2012. PMID: 22675486
- Mullol J, Crespo C, Carré C, Brosa M. Pharmacoeconomics of Cyclamen europaeum in the Management of Acute Rhinosinusitis. The Laryngoscope (Official Journal of The American Laryngological, Rhinological and Otological Society) 123: 2620-2625, 2013. PMID: 23670920.
Quality & Commitment
-
MANUFACTURED TO THE HIGHEST STANDARDS OF QUALITY
Watch Nasodren® manufacturing process
-
HARTINGTON GROUP: AN ISO 9001:2008 CERTIFIED COMPANY
Watch Hartington Group corporate video